<DOC>
	<DOCNO>NCT00517842</DOCNO>
	<brief_summary>The investigational product specially formulate TCM administer form capsule . Basic pre-clinical study suggest may good immunomodulating function , increase activity T-cells , B-cells NK cell , enhance mitochondrial antioxidant status various tissue include brain tissue . Therefore , formulation may special value improve symptom Parkinson 's disease patient . The purpose study determine efficacy safety ViNeuro patient Parkinson 's disease .</brief_summary>
	<brief_title>A Triple-blinded , Randomised , Placebo-controlled Trial Examine Efficacy Safety ViNeuro Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>A subject eligible study participation he/she meet follow criterion : 1 . Age least 30 year 2 . Diagnosis symptomatic , idiopathic Parkinson ' disease use The United Kingdom Parkinson 's Disease Society Brain Bank Diagnostic Criteria ( Appendix 3 protocol ) 3 . Stage 14 modify Hoehn Yahr scale ( Appendix 4 protocol ) 4 . Possesses three four cardinal sign Parkinson 's disease , i.e . rigidity , bradykinesia , rest tremor postural instability , without know suspected cause parkinsonism 5 . If receive levodopa symptomatic treatment , subject show good response stable dosage least 1 month prior study entry 6 . Voluntarily sign date Informed Consent Form , approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) , prior studyspecific procedure . A subject exclude study he/she meet follow criterion : 1 . Presence atypical parkinsonian syndrome 2 . Dementia define MiniMental State Examination score ( Appendix 5 protocol ) 22 less 3 . Serious concurrent illness , active cardiac , renal , liver , neoplastic disease 4 . Used centrally active therapy , e.g . hypnotic , antidepressant , anxiolytic , within 60 day study entry 5 . Used methylphenidate , cinnarizine , reserpine , amphetamine , monoamine oxidaseA inhibitor , e.g . pargyline , phenelzine , tranylcpromine , within 3 month study entry 6 . Has history receive neuroleptic 7 . Used alphamethyldopa flunarizine within 6 month study entry 8 . Females pregnant breastfeeding . 9 . Subjects currently participate another investigational study take investigational drug within last 4 week prior screen study ( Visit 1 ) . 10 . Subjects take traditional Chinese medication , take traditional Chinese medication within last 2 week prior screen study ( Visit 1 ) . 11 . Any criterion , , opinion investigator , suggest subject would compliant study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Parkinson 's disease</keyword>
</DOC>